REGISTER
Dr Yelena Y. Janjigian at ASCO 2025 -- MedJ Interview
The discussion highlights why Dr Yelena Y. Janjigian at ASCO 2025 -- MedJ Interview deserves closer attention. By organizing evidence on ASCO, III, FLOT, it turns scattered results into practical conclusions for clinicians and patients.

MedJ takes you straight to ASCO 2025.

Professor Yelena Y. Janjigian from Memorial Sloan Kettering Cancer Center presented groundbreaking Phase III data on the world's first perioperative immunotherapy regimen—durvalumab combined with FLOT chemotherapy for resectable gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJC)—and decoded the new treatment strategy in depth.

0
0
Loading